- Home
- LBGJ vs CASI Comparison
LBGJ vs CASI Comparison
Compare LBGJ & CASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LBGJ
- CASI
- Stock Information
- Founded
- LBGJ 2007
- CASI 1991
- Country
- LBGJ China
- CASI China
- Employees
- LBGJ N/A
- CASI N/A
- Industry
- LBGJ
- CASI Biotechnology: Pharmaceutical Preparations
- Sector
- LBGJ
- CASI Health Care
- Exchange
- LBGJ NYSE
- CASI Nasdaq
- Market Cap
- LBGJ 24.7M
- CASI 20.5M
- IPO Year
- LBGJ 2024
- CASI 1996
- Fundamental
- Price
- LBGJ $1.49
- CASI $1.20
- Analyst Decision
- LBGJ
- CASI Strong Buy
- Analyst Count
- LBGJ 0
- CASI 1
- Target Price
- LBGJ N/A
- CASI $4.00
- AVG Volume (30 Days)
- LBGJ 72.0K
- CASI 297.3K
- Earning Date
- LBGJ 06-17-2025
- CASI 08-15-2025
- Dividend Yield
- LBGJ N/A
- CASI N/A
- EPS Growth
- LBGJ N/A
- CASI N/A
- EPS
- LBGJ N/A
- CASI N/A
- Revenue
- LBGJ $11,781,015.00
- CASI $31,368,000.00
- Revenue This Year
- LBGJ N/A
- CASI N/A
- Revenue Next Year
- LBGJ N/A
- CASI N/A
- P/E Ratio
- LBGJ N/A
- CASI N/A
- Revenue Growth
- LBGJ 21.82
- CASI 8.39
- 52 Week Low
- LBGJ $1.02
- CASI $1.10
- 52 Week High
- LBGJ $5.50
- CASI $7.67
- Technical
- Relative Strength Index (RSI)
- LBGJ N/A
- CASI 29.29
- Support Level
- LBGJ N/A
- CASI $1.22
- Resistance Level
- LBGJ N/A
- CASI $1.42
- Average True Range (ATR)
- LBGJ 0.00
- CASI 0.28
- MACD
- LBGJ 0.00
- CASI -0.04
- Stochastic Oscillator
- LBGJ 0.00
- CASI 5.49
About LBGJ LI BANG INTERNATIONAL CORPORATION I
Li Bang International Corp Inc is a holding company. The firm through its subsidiaries engages in designing, developing, producing, and selling stainless steel commercial kitchen equipment in China under its own Libang brand. In addition, its subsidiaries provide customers with comprehensive services, from commercial kitchen design in the early stage to equipment installation and after-sales maintenance.
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.